» Articles » PMID: 36344998

Achieving Malaria Testing and Treatment Targets for Children Under Five in Mozambique: a Cost-effectiveness Analysis

Overview
Journal Malar J
Publisher Biomed Central
Specialty Tropical Medicine
Date 2022 Nov 7
PMID 36344998
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The entire population of Mozambique is at risk for malaria, which remains one of the leading causes of death. The 2017-2022 National Malaria Strategic Plan focuses on reducing malaria morbidity and mortality in high- and low-transmission areas. This study aimed to estimate the costs and health benefits of six variations of the World Health Organization's "test-and-treat" strategy among children under five.

Methods: A decision tree model was developed that estimates the costs and health outcomes for children under five. Data on probabilities, costs, weights for disability-adjusted life years (DALYs), and quality-adjusted life years (QALYs) were based on peer-reviewed, grey literature, and primary data analysis of the 2018 Malaria Indicator Survey. Six scenarios were compared to the status quo and calculated the incremental cost-effectiveness ratio (ICER) in terms of cost per QALY gained, DALY averted, and life saved. Deterministic and probabilistic sensitivity analyses were conducted to understand the effect of parameter uncertainty on the findings.

Results: In the base case, reaching the target of 100% testing with rapid diagnostic tests (RDTs; Scenario 1) is more cost-effective than improving the testing rate alone by 10% (Scenario 2). Achieving a 100% (Scenario 3) or a 10% increase in treatment rate (Scenario 4) have ICERs that are lower than Scenarios 1 and 2. Both Scenarios 5 and 6, which represent combinations of Scenarios 1-4, have lower ICERs than their constituent strategies on their own, which suggests that improvements in treatment are more cost-effective than improvements in testing alone. These results held when DALYs averted or lives saved were used as health outcomes. Deterministic and probabilistic sensitivity analyses revealed that the cost-effectiveness of Scenarios 1-6 are subject sensitive to parameter uncertainty, though Scenarios 4 and 5 are the optimal choice when DALYs averted or QALYs gained were used as the measure of health outcomes across all cost-effectiveness thresholds.

Conclusions: Improving testing rates alone among children at risk for malaria has the potential to improve health but may not be the most efficient use of limited resources. Instead, small or large improvements in treatment, whether alone or in conjunction with improvements in testing, are the most cost-effective strategies for children under five in Mozambique.

Citing Articles

Prediction of malaria positivity using patients' demographic and environmental features and clinical symptoms to complement parasitological confirmation before treatment.

Ojurongbe T, Afolabi H, Bashiru K, Sule W, Akinde S, Ojurongbe O Trop Dis Travel Med Vaccines. 2023; 9(1):24.

PMID: 38098124 PMC: 10722830. DOI: 10.1186/s40794-023-00208-7.

References
1.
Vallejo-Torres L, Garcia-Lorenzo B, Castilla I, Valcarcel-Nazco C, Garcia-Perez L, Linertova R . On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?. Value Health. 2016; 19(5):558-66. DOI: 10.1016/j.jval.2016.02.020. View

2.
Prudhomme OMeara W, Menya D, Laktabai J, Platt A, Saran I, Maffioli E . Improving rational use of ACTs through diagnosis-dependent subsidies: Evidence from a cluster-randomized controlled trial in western Kenya. PLoS Med. 2018; 15(7):e1002607. PMC: 6049880. DOI: 10.1371/journal.pmed.1002607. View

3.
Bowser D, Okunogbe A, Oliveras E, Subramanian L, Morrill T . A Cost-Effectiveness Analysis of Community Health Workers in Mozambique. J Prim Care Community Health. 2015; 6(4):227-32. DOI: 10.1177/2150131915579653. View

4.
Nhama A, Bassat Q, Enosse S, Nhacolo A, Mutemba R, Carvalho E . In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique. Malar J. 2014; 13:309. PMC: 4132202. DOI: 10.1186/1475-2875-13-309. View

5.
Snow R, Sartorius B, Kyalo D, Maina J, Amratia P, Mundia C . The prevalence of Plasmodium falciparum in sub-Saharan Africa since 1900. Nature. 2017; 550(7677):515-518. PMC: 5660624. DOI: 10.1038/nature24059. View